In 2023, Richards and his colleagues published a comparison between patients taking semaglutide and those using lisdexamfetamine and topiramate, a combination medication already approved for binge eating or weight loss
Since they debuted, injectable GLP-1 drugs like Ozempic have been in high demand
In addition, glucagon-like peptide-1 analogues (GLP-1a) have garnered increased attention as pharmacological treatments capable of improving cognitive functions, supported by positive results from preclinical studies and some observational research [6, 7]
This tri-receptor activity is what fundamentally distinguishes Retatrutide from all preceding incretin research compounds, including dual agonists like Tirzepatide (GLP-1R/GIPR) and single agonists like Semaglutide (GLP-1R only), and is the basis for its position at the leading edge of metabolic peptide research
Sleep Stack Deep sleep + metabolic recovery support